Spero Therapeutics Announces Underwriters’ Option Exercise

11/13/17

CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections, today announced that the underwriters of its previously announced initial public offering have exercised their option to purchase an additional 471,498 shares during the option period. Including the option exercise, total gross proceeds from the offering of an aggregate of 5,971,498 shares were approximately $83.6 million, before deducting the underwriting discount and estimated offering expenses payable by Spero. This represents approximately $6.6 million more gross proceeds than the gross proceeds on the initial closing. Spero’s common stock began trading on The Nasdaq Global Select Market on November 2, 2017 under the symbol “SPRO”.

BofA Merrill Lynch, Cowen and Stifel acted as joint book-running managers for the offering. Oppenheimer & Co. acted as a co-manager for the offering.

About Spero

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug resistant bacterial infections.

It's on us. Share your news here.

Submit your stories and articles to citybizlist today.